The objective is to determine whether the COVID-19 infection is associated with intestinal dysbiosis and contributes to increased inflammation and Cytokine Release Syndrome (CRS) and whether the subject’s initial microbiome confers protection or susceptibility to infection or modifies the response to immunotherapies.

Principal Investigator: Yolanda Sanz (IATA)

We use cookies on this site to improve your user experience. More info. ACEPTAR

Aviso de cookies